B
Barbara Peter
Researcher at Medical University of Vienna
Publications - 47
Citations - 1328
Barbara Peter is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Systemic mastocytosis & Midostaurin. The author has an hindex of 18, co-authored 43 publications receiving 1120 citations. Previous affiliations of Barbara Peter include University of Veterinary Medicine Vienna.
Papers
More filters
Journal ArticleDOI
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
Philipp Rathert,Mareike Roth,Tobias Neumann,Felix Muerdter,Jae Seok Roe,Matthias Muhar,Sumit Deswal,Sabine Cerny-Reiterer,Barbara Peter,Julian Jude,Thomas Hoffmann,Łukasz M. Boryń,Elin Axelsson,Norbert Schweifer,Ulrike Tontsch-Grunt,Lukas E. Dow,Davide Gianni,Mark Pearson,Peter Valent,Alexander Stark,Norbert Kraut,Christopher R. Vakoc,Johannes Zuber +22 more
TL;DR: The results identify and validate WNT signalling as a driver and candidate biomarker of primary and acquired BET resistance in leukaemia, and implicate the rewiring of transcriptional programs as an important mechanism promoting resistance to BET inhibitors and, potentially, other chromatin-targeted therapies.
Journal ArticleDOI
Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536
Karoline V. Gleixner,Veronika Ferenc,Barbara Peter,Alexander Gruze,Renata A. Meyer,Emir Hadzijusufovic,Sabine Cerny-Reiterer,Matthias Mayerhofer,Winfried F. Pickl,Christian Sillaber,Peter Valent +10 more
TL;DR: Plk1 is expressed in CML cells and may represent a novel, interesting target in imatinib-sensitive and imatinIB-resistant CML.
Journal ArticleDOI
Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
Karl J. Aichberger,Karoline V. Gleixner,Irina Mirkina,Sabine Cerny-Reiterer,Barbara Peter,Barbara Peter,Veronika Ferenc,Michael Kneidinger,Christian Baumgartner,Matthias Mayerhofer,Alexander Gruze,Winfried F. Pickl,Christian Sillaber,Peter Valent +13 more
TL;DR: The data show that KIT D816V suppresses expression of proapoptotic Bim in neoplastic MCs, and targeting of Bcl-2 family members by drugs promoting Bim (re)-expression, or by BH3-mimetics such as obatoclax, may be an attractive therapy concept in SM.
Journal ArticleDOI
Midostaurin: a magic bullet that blocks mast cell expansion and activation.
Peter Valent,Cem Akin,Karin Hartmann,Tracy I. George,Karl Sotlar,Barbara Peter,Karoline V. Gleixner,Katharina Blatt,W. R. Sperr,Paul W. Manley,Olivier Hermine,Hanneke C. Kluin-Nelemans,Michel Arock,H.-P. Horny,Andreas Reiter,Jason Gotlib +15 more
TL;DR: Encouraging results have been obtained with the drug in a recent multi-center phase II trial in patients with advanced SM, with an overall response rate of 60% and a substantial decrease in the burden of neoplastic MC in various organs and midostaurin was found to improve mediator-related symptoms and quality of life.
Journal ArticleDOI
Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML
Irina Sadovnik,Andrea Hoelbl-Kovacic,Harald Herrmann,Gregor Eisenwort,Sabine Cerny-Reiterer,Wolfgang Warsch,Wolfgang Warsch,Gregor Hoermann,Georg Greiner,Katharina Blatt,Barbara Peter,Gabriele Stefanzl,Daniela Berger,Martin Bilban,Susanne Herndlhofer,Heinz Sill,Wolfgang R. Sperr,Berthold Streubel,Christine Mannhalter,Tessa L. Holyoake,Veronika Sexl,Peter Valent +21 more
TL;DR: CD25 is a novel STAT5-dependent marker of CML LSCs and may be useful for LSC detection and LSC isolation in clinical practice and basic science and may pave the way for the development of new more effective LSC-eradicating treatment strategies in CML.